Welcome to Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Latest rankings (SJR/Scimago 2020): equivalent Impact Factor (eIF) = 5.1; SJR = 1.262. Ranked 102 of 297 pharmacology journals worldwide (based on eIF) and ranked 76 of 793 of all general medicine journals worldwide (based on eIF).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)

Hichem Aouina, Anis Bamri, Aurélien Vesin, Karine Danno, Eléonore Aubry, Cécile Faure, Naoual Boujedaini

Articles 2021

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi

Advances in safe insulin infusions

Fred Massoomi, Maureen Burger, Christine de Vries

Therapeutics for paediatric oncological emergencies

Karen Ka Yan Leung, Kam Lun Hon, Wun Fung Hui, Alexander KC Leung, Chi Kong Li

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi